XL092-001

A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors

  • Code NKI: M21EXL
  • Code firma: XL092-001
  • Code clinicaltrials.gov: NCT03845166

Principal Investigator

Dr. F. Opdam

Drugs

XL092; multikinase inhibitor of MET, VEGFR2, AXL, MER

  • Cohort A: Expansion monotherapy; ccRCC – closed
  • Cohort B : Expansion monotherapy; nonccRCC (non-clear cell Renal Cell Carcinoma) – closed
  • Cohort E: Expansion atezolizumab combination; nonccRCC (non-clear cell Renal Cell Carcinoma) – closed
  • Cohort F: Expansion atezolizumab combination; HR+ BC – open
  • Cohort G: Expansion atezolizumab combination; mCRPC – closed

Summary

This is a Phase 1, open-label, dose-escalation and expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect on biomarkers of XL092 administered alone, in combination with atezolizumab, and in combination with avelumab to subjects with advanced solid tumors.

Read more on clinicaltrials.gov

Inclusion for this trial is currently on hold.

Patient population

Tumor type: RCC, Renal Cell Carcinoma / Breast Cancer, Breast Carcinoma / Prostate Cancer, Prostate Carcinoma
Tumor characteristics: Other, Unknown / HR+ (hormone receptor positive)